Shanghai Henlius Biotech Sustainability Profile
Shanghai Henlius Biotech, also known as Henlius, is a prominent biopharmaceutical company headquartered in Shanghai, China. Founded in 2010, the company has rapidly established itself in the biotechnology industry, focusing on the research, development, and manufacturing of innovative monoclonal antibodies for the treatment of various diseases, including cancer and autoimmune disorders. With a strong operational presence in both domestic and international markets, Henlius has achieved significant milestones, including the successful launch of its flagship products, which are distinguished by their high quality and affordability. The company is recognised for its commitment to advancing biopharmaceutical solutions, positioning itself as a key player in the global market. Henlius continues to expand its portfolio, aiming to enhance patient outcomes through cutting-edge therapies.
DitchCarbon Score
How does Shanghai Henlius Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shanghai Henlius Biotech's score of 42 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shanghai Henlius Biotech's reported carbon emissions
In 2024, Shanghai Henlius Biotech reported total carbon emissions of approximately 21.1 million kg CO2e, comprising about 6.5 million kg CO2e from Scope 1, approximately 14.2 million kg CO2e from Scope 2, and about 347,190 kg CO2e from Scope 3 emissions related to waste generated in operations. This data reflects a slight decrease from 2023, where total emissions were approximately 22.3 million kg CO2e, with Scope 1 emissions at about 6.9 million kg CO2e and Scope 2 emissions at approximately 15.1 million kg CO2e. The company has not set specific reduction targets or initiatives as part of its climate commitments, and there are no reported SBTi (Science Based Targets initiative) reduction targets. Emissions data is cascaded from its parent company, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., indicating a corporate family relationship that influences its reporting and performance metrics. Overall, Shanghai Henlius Biotech is actively monitoring its carbon footprint, but further commitments and reduction strategies are necessary to align with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 5,534,750 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 14,133,210 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000 | 000,000 | 000,000 |
How Carbon Intensive is Shanghai Henlius Biotech's Industry?
How Carbon Intensive is Shanghai Henlius Biotech's Location?
Shanghai Henlius Biotech's Scope 3 Categories Breakdown
Shanghai Henlius Biotech's Scope 3 emissions, which increased by 15% last year and increased by approximately 17% since 2022, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 2% of total emissions under the GHG Protocol, with "Waste Generated in Operations" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
Shanghai Henlius Biotech's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Shanghai Henlius Biotech has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.